ArticleLeukemia2017
Impact of pretreatment characteristics and salvage strategy on outcome in patients with relapsed acute myeloid leukemia.
Open access · bronzeAbstract read
In one paragraph
Article in Leukemia, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
5.7field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 74 citations in OpenAlex.
- A phase 2 pilot study of umbilical cord blood infusion as an adjuvant consolidation therapy in elderly patients with acute myeloid leukemia.Signal transduction and targeted therapy · 2024Trial
- Trial
- Article
- Cost-effectiveness of upfront vs delayed allogeneic hematopoietic stem cell transplant for intermediate risk AML.Blood advances · 2025Article
- Phase I first-in-human dose escalation study of the oral casein kinase 1α and cyclin dependent kinase 7/9 inhibitor BTX A51 in advanced MDS and AML.Journal of hematology & oncology · 2025Article
- Venetoclax-based salvage therapy as a bridge to transplant is feasible and effective in patients with relapsed/refractory AML.Blood advances · 2025Article
- Inhibition of CRM1 reverses hypoxia-driven chemoresistance in acute myeloid leukemia via overcoming HIF-1α-mediated lysosomal sequestration.Frontiers in immunology · 2025Article
- Outcomes and genetic dynamics of acute myeloid leukemia at first relapse.Haematologica · 2024Article
- Acute myeloid leukemia at first relapse: approaching the precipice.Haematologica · 2024Article
- Exploration of ETV6::ABL1-positive AML with concurrent NPM1 and FLT3-ITD mutations.Annals of hematology · 2024Article
- Molecular relapse after first-line intensive therapy in patients with CBF or NPM1-mutated acute myeloid leukemia - a FILO study.Leukemia · 2024Article
- CAR-T Cells in Acute Myeloid Leukemia: Where Do We Stand?Biomedicines · 2024Review
- Chidamide, Decitabine, Cytarabine, Aclarubicin, and Granulocyte Colony-stimulating Factor Therapy for Patients with Relapsed/Refractory Acute Myeloid Leukemia: A Retrospective Study from a Single-Center.Current medical science · 2023Article
- A clinical trial of zosuquidar plus gemtuzumab ozogamicin (GO) in relapsed or refractory acute myeloid leukemia (RR AML): evidence of efficacy based on leukemic blast P-glycoprotein functional phenotype.Cancer chemotherapy and pharmacology · 2023Article
- The Use of Gemtuzumab Ozogamicin as Salvage Therapy in Patients with Acute Myeloid Leukemia: A Monocentric Real-World Experience.Medicina (Kaunas, Lithuania) · 2023Observational
- Synergistic efficacy of homoharringtonine and venetoclax on acute myeloid leukemia cells and the underlying mechanisms.Annals of translational medicine · 2022Article
- Chemotherapy or Allogeneic Stem Cell Transplantation as Salvage Therapy for Patients with Refractory Acute Myeloid Leukemia: A Multicenter Analysis.Acta haematologica · 2022Article
- Transcriptome-Wide Analysis of RNA NFrontiers in genetics · 2022Article
- Review
- Compassionate use of glasdegib in combination with low-dose cytarabine for relapsed, refractory acute myeloid leukemia or high-risk myelodysplastic syndrome.Annals of hematology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
33 authors at 16 institutions in 2 countries.
R F SchlenkDepartment of Internal Medicine III, University Hospital of Ulm, Ulm, Germany.
P FrechDepartment of Internal Medicine III, University Hospital of Ulm, Ulm, Germany.
D WeberDepartment of Internal Medicine III, University Hospital of Ulm, Ulm, Germany.
P BrossartDepartment of Internal Medicine III, University Hospital of Bonn, Bonn, Germany.
H-A HorstDepartment of Internal Medicine II, University Hospital Schleswig-Holstein Campus Kiel, Kiel, Germany.
D KraemerDepartment of Oncology and Hematology, Klinikum Oldenburg, Oldenburg, Germany.
G HeldDepartment of Internal Medicine I, University Hospital of Saarland, Homburg, Germany.
M RinghofferDepartment of Internal Medicine III, Städtisches Klinikum Karlsruhe, Karlsruhe, Germany.
A BurchardtDepartment of Hematology/Oncology, University-hospital Giessen, Giessen, Germany.
G KobbeDepartment of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany.
K GötzeDepartment of Internal Medicine III, Technical University of Munich, Munich, Germany.
D NachbaurDepartment of Internal Medicine V, University Hospital Innsbruck, Innsbruck, Austria.
T FischerDepartment of Medicine III, Johannes Gutenberg-University Mainz, Mainz, Germany.
M LübbertDepartment of Hematology and Oncology, University Hospital of Freiburg, Freiburg, Germany.
H R SalihDepartment of Hematology and Oncology, Eberhard-Karls University, Tübingen, Germany.
H SalwenderDepartment of Hematology/Oncology, Asklepios Klinik Altona, Hamburg, Germany.
G WulfDepartment of Hematology and Oncology, University Hospital of Göttingen, Göttingen, Germany.
E KollerDepartment of Hematology/Oncology, Hanuschkrankenhaus, Wien, Austria.
M WattadDepartment of Hematology Oncology, Kliniken Essen-Süd, Essen, Germany.
W FiedlerDepartment of Internal Medicine II, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
S KremersDepartment of Hematology/Oncology, Caritas-Krankenhaus, Lebach, Germany.
H KirchenDepartment of Hematology/Oncology, Krankenhaus der Barmherzigen Brüder, Trier, Germany.
B HertensteinDepartment of Internal Medicine I, Klinikum Bremen Mitte, Bremen, Germany.
P PaschkaDepartment of Internal Medicine III, University Hospital of Ulm, Ulm, Germany.
V I GaidzikDepartment of Internal Medicine III, University Hospital of Ulm, Ulm, Germany.
V TeleanuDepartment of Internal Medicine III, University Hospital of Ulm, Ulm, Germany.
M HeuserDepartment of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.
F TholDepartment of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.
K DöhnerDepartment of Internal Medicine III, University Hospital of Ulm, Ulm, Germany.
J KrauterDepartment of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.
A GanserDepartment of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.
H DöhnerDepartment of Internal Medicine III, University Hospital of Ulm, Ulm, Germany.
the German-Austrian AMLSG
Medizinische Hochschule Hannover · DEUniversity Hospital Ulm · DEAsklepios Klinik Altona · DEHanusch Hospital · ATJohannes Gutenberg University Mainz · DEKlinikum Oldenburg · DEKrankenhaus der Barmherzigen Brüder Trier · DEUniversität Hamburg · DEUniversitätsklinikum Gießen und Marburg · DEUniversity Hospital Bonn · DEHeinrich Heine University Düsseldorf · DEKlinikum Bremen-Mitte · DENational Center for Tumor Diseases · DEStädtisches Klinikum Karlsruhe · DEUniversity Hospital Innsbruck · ATUniversity Medical Center Freiburg · DE
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Salvage TherapyAdolescentAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsFemaleHematopoietic Stem Cell TransplantationHumansLeukemia, Myeloid, AcuteMaleMiddle AgedPrognosisRecurrenceTreatment OutcomeYoung Adult
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.